Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection
NCT04978051
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
73
Enrollment
OTHER
Sponsor class
Conditions
COVID-19 Pneumonia
Interventions
DRUG:
Firazyr
OTHER:
SoC
Sponsor
Sebastian Videla